TTNP Titan Pharmaceuticals Inc.

0.47
+0.03  (+8%)
Previous Close 0.44
Open 0.46
Price To Book 2.24
Market Cap 6,715,774
Shares 14,261,571
Volume 611,971
Short Ratio
Av. Daily Volume 297,367

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. Some Titan Pharmaceuticals (NASDAQ:TTNP) Shareholders Have Copped A 99% Share Price Wipe Out
  2. The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission
  3. Titan Pharmaceuticals Reports Second Quarter 2019 Financial Results
  4. Q2 Earnings Preview For Titan Pharmaceuticals
  5. Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow
  6. Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering
  7. Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark
  8. What Does Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) Balance Sheet Tell Us About It?
  9. Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine
  10. Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®
  11. TTNP: A+ Partnerships: AllianceRx, AppianRx & Accredo
  12. Edited Transcript of TTNP earnings conference call or presentation 15-May-19 8:30pm GMT
  13. Titan Pharmaceuticals: 1Q Earnings Snapshot
  14. Titan Pharmaceuticals Reports First Quarter 2019 Financial Results
  15. Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®
  16. Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow
  17. Edited Transcript of TTNP earnings conference call or presentation 2-Apr-19 12:30pm GMT
  18. Titan Pharmaceuticals And Molteni Announce Positive EU CHMP Opinion For Probuphine®
  19. Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast
  20. TTNP: EMA Approval of Probuphine Expected 2Q:19